Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Subscribe To Our Newsletter & Stay Updated